Editorial
Nature Biotechnology 26, 1 (2008)
doi:10.1038/nbt0108-1
The regulator disapproves
Abstract
Pressure is mounting on the US Food and Drug Administration (FDA) to explain its decision to ignore an advisory committee's positive recommendation for the cancer vaccine Provenge.
